Definition: Adenocarcinoma is a type of malignant tumor that originates from glandular epithelial cells. These tumors produce glandular or mucinous secretions.
Common Sites
- Lung (most common type of non-small cell lung cancer)
- Colon and rectum
- Pancreas
- Prostate
- Breast
- Esophagus and stomach
- Endometrium
Pathophysiology
- Arises from gland-forming epithelial cells lining organs and ducts.
- Characterized by abnormal proliferation with glandular differentiation and mucin production.
- Often associated with mutations in oncogenes (e.g., KRAS, EGFR) and tumor suppressors (e.g., TP53).
Clinical Relevance
- Adenocarcinomas often respond to targeted therapies directed at specific molecular alterations (e.g., EGFR inhibitors in lung adenocarcinoma).
- Histological subtype guides chemotherapy regimens and prognosis.
- Monitoring tumor markers such as CEA (carcinoembryonic antigen) may be useful in some adenocarcinomas (e.g., colorectal).
Pharmacist Considerations
- Understand common chemotherapy and targeted agents used for adenocarcinomas (e.g., pemetrexed, EGFR TKIs).
- Be aware of molecular testing requirements (e.g., EGFR, ALK in lung adenocarcinoma) that influence treatment choice.
- Counsel patients on side effects of therapies tailored for adenocarcinomas.
Key Takeaway:
Adenocarcinoma is a malignant glandular tumor common in many organs, often treated with site-specific chemotherapy and targeted agents, with molecular profiling playing a critical role in management.